Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Accounts Payables: 2011-2024

Historic Accounts Payables for Adma Biologics (ADMA) over the last 11 years, with Dec 2024 value amounting to $20.2 million.

  • Adma Biologics' Accounts Payables rose 49.94% to $24.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.0 million, marking a year-over-year increase of 49.94%. This contributed to the annual value of $20.2 million for FY2024, which is 29.11% up from last year.
  • Latest data reveals that Adma Biologics reported Accounts Payables of $20.2 million as of FY2024, which was up 29.11% from $15.7 million recorded in FY2023.
  • Adma Biologics' 5-year Accounts Payables high stood at $20.2 million for FY2024, and its period low was $11.1 million during FY2020.
  • For the 3-year period, Adma Biologics' Accounts Payables averaged around $16.4 million, with its median value being $15.7 million (2023).
  • Data for Adma Biologics' Accounts Payables shows a peak YoY increased of 29.11% (in 2024) over the last 5 years.
  • Over the past 5 years, Adma Biologics' Accounts Payables (Yearly) stood at $11.1 million in 2020, then rose by 12.24% to $12.4 million in 2021, then increased by 6.43% to $13.2 million in 2022, then increased by 18.38% to $15.7 million in 2023, then climbed by 29.11% to $20.2 million in 2024.